{"filings":[{"id":655436,"accession_number":"0001213900-26-060879","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-05-26T15:05:14+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa and Bio Insights amend asset purchase agreement; delete provision for 12% management share issuance","event_type":"m_and_a","confidence":"high","bullets":["Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.","$30M purchase price for PanOmics multi-omics assay know-how, paid in Series A Convertible Preferred, unchanged.","Amendment confirms no other changes to the Asset Purchase Agreement remain in full force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501796,"accession_number":"0001213900-26-058575","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-05-18T21:29:05+00:00","items":["8.01"],"status":"ready","headline":"Profusa submits advance notice under equity line; price at 97% of lowest VWAP, cap $300k, 9.99% of shares","event_type":"other_material","confidence":"high","bullets":["Advance Notice submitted to Ascent Partners Fund LLC for purchase of common stock under equity line arrangement.","Terms: up to 9.99% of shares outstanding per advance, capped at $300,000 per notice.","Purchase price set at 97% of lowest VWAP over ten trading days prior to advance date.","True-Up Mechanism: additional shares issued if adjusted price during sale period is lower than closing price.","Payment to occur upon share delivery, not upon Ascent's exit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":453156,"accession_number":"0001213900-26-057182","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-05-15T12:58:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profusa transfers to Nasdaq Capital Market on May 15, 2026, under panel compliance plan","event_type":"regulatory","confidence":"high","bullets":["Transfer to Nasdaq Capital Market effective May 15, 2026, per hearings panel confirmation.","Company must meet interim milestones for bid price (Rule 5550(a)(2)) and equity (Rule 5550(b)(2)) compliance.","Previously disclosed panel decision required filing transfer application by May 11, 2026, which was completed.","No assurance that Profusa will satisfy all conditions or maintain its Nasdaq listing.","Press release issued May 15, 2026, announcing the transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96338,"accession_number":"0001213900-26-053535","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profusa granted Nasdaq exception to continue listing; transfer to Capital Market by July 6, 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted exception to continue listing; must comply with Bid Price Rule and Equity Rule by July 6, 2026.","Company's listing to transfer from Nasdaq Global Market to Nasdaq Capital Market.","Company must meet interim milestones; Panel may reconsider terms based on developments.","No assurance of compliance; company evaluating conditions and intends to act within deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96337,"accession_number":"0001213900-26-049432","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["1.01","2.03","3.03","3.01","9.01"],"status":"ready","headline":"Profusa faces Nasdaq delisting for MVPHS failure; amends debt and warrant terms","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of non-compliance with $15M MVPHS Rule; deadline missed April 27, 2026; response due May 5.","Also under Panel review for bid price ($1.00) and MVLS ($50M) deficiencies; no assurance of continued listing.","Amended $1.87M promissory note with NorthView Sponsor: non-interest, maturity Dec 31, 2026, convertible at 95% of close or $0.35 floor.","Amendment caps conversion shares at 19.99% of outstanding unless stockholder approval obtained within 90 days.","Amended warrant with Ascent Partners: removed automatic conversion in fundamental transactions; warrant for 3.33M shares at $0.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96336,"accession_number":"0001213900-26-048039","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Profusa acquires PanOmics platform assets for $30M in convertible preferred stock","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $30M via Series A Convertible Preferred Stock, convertible to common after 1 year.","Seller retains all patent rights; buyer gets know-how, data, algorithms, software for multi-omics platform.","Subject to Nasdaq stockholder approval by June 30, 2026; closing target by Sep 30, 2026.","Seller receives 3% royalty on net revenue from commercialization; 5-year lock-up on shares.","Company seeks to raise $10M additional equity financing concurrently with closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96335,"accession_number":"0001213900-26-047578","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Profusa Issues $1.11M Convertible Note and Warrant to Ascent Partners Fund LLC","event_type":"debt","confidence":"high","bullets":["Issued $1,111,111.11 principal Senior Secured Convertible Promissory Note to Ascent Partners Fund LLC for $1,000,000 purchase price, maturing April 20, 2027, with 12% annual interest.","Issued warrant to purchase up to 3,333,333 shares of common stock at $0.50 per share, exercisable for five years.","Ascent entered into a 120-day lock-up agreement for shares underlying the warrant, expiring August 22, 2026.","Side letter with Ascent waived certain defaults and increased warrant shares from 1,111,111 to 3,333,333.","Note is secured by substantially all of Profusa's assets; conversion price $0.50 per share with 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96334,"accession_number":"0001213900-26-040111","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Profusa signs LOI to buy PanOmics assets for $30M equity; issues $555k convertible note","event_type":"m_and_a","confidence":"high","bullets":["Non-binding LOI to acquire Bio Insights' PanOmics assay for $30M in stock (460k common + 59.54M conversion shares) plus 3% annual net revenue royalty.","Issued $555,556 senior secured convertible note to Ascent (12% interest, due 2027, convertible at $0.50) and warrant for 1.11M shares at $0.50.","Amendment No. 4 allows up to $12.2M additional notes with at least 10% OID; $1.67M principal release condition.","Acquisition requires shareholder vote by June 30, 2026 and $10M equity financing within 30 days post-closing.","Bio Insights gets one board nominee; management retention shares (12% fully diluted) for CEO/CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110155,"accession_number":"0001213900-26-034706","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa extends $2.5M promissory note maturity to Dec 31, 2026","event_type":"debt","confidence":"high","bullets":["Amendment effective March 20, 2026 extends maturity of note from NorthView Sponsor I LLC.","Principal balance up to $2.5M payable on Dec 31, 2026 or earlier at the company's election.","All other terms of the original Amended and Restated Promissory Note remain unchanged.","Extension avoids immediate maturity; no new borrowing or other modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110154,"accession_number":"0001213900-26-027218","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.02","2.01","3.01","9.01"],"status":"ready","headline":"Profusa receives Nasdaq delisting notice; terminates Bitcoin treasury strategy, liquidates holdings","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Global Market delisting notice for failure to meet $50M MVLS and $1.00 bid price; deadline March 10, 2026 missed.","Company terminates Bitcoin treasury reserve strategy and will liquidate entire ~16.51 Bitcoin holdings (~$2M cost).","Account Control Agreement with BitGo terminated in connection with Bitcoin strategy exit; no early termination penalties.","Proceeds from Bitcoin sale to be used for general corporate purposes.","Company intends to appeal delisting determination; hearing request stays suspension pending Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110153,"accession_number":"0001213900-26-016496","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI","event_type":"other_material","confidence":"high","bullets":["Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).","Collaboration to support U.S. commercialization of Lumee wearable continuous tissue oxygen monitoring for critical limb ischemia.","Potential new indications include cardiovascular, renal, multi-organ, and orthopedic postoperative perfusion monitoring.","Profusa CEO notes over $100M invested in Lumee; Mayo retains financial interest for not-for-profit mission.","Financial terms include royalties on net sales, milestone payments, and share of sublicense income."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110152,"accession_number":"0001213900-26-012552","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Profusa announces 1-for-75 reverse stock split effective Feb 9, 2026","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:75; effective 12:01 a.m. ET on Feb 9, 2026.","Outstanding shares drop from ~92.4M to ~1.2M; authorized shares unchanged at 601M.","No fractional shares issued; fractional holders receive cash in lieu.","Stock continues trading on Nasdaq under symbol PFSA with new CUSIP 74319X207.","Historical net loss per share recalculated on post-split basis (e.g., FY 2024: $(357.13) per share)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110151,"accession_number":"0001213900-26-010808","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Profusa shareholders approve reverse stock split authorization up to 1-for-200","event_type":"other_material","confidence":"high","bullets":["Proposal to authorize Board to effect reverse splits at ratios 1-for-30 to 1-for-200 before Jan 27, 2028 passed with 30.8M For, 6.0M Against.","Ratification of CBIZ CPAs P.C. as auditor for FY 2025 approved with 35.6M For, 0.7M Against.","Adjournment proposal passed with 32.1M For, 4.1M Against.","Quorum of 36.8M shares (42.6% of outstanding) was present at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126712,"accession_number":"0001213900-25-126316","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa enters Amendment No. 3 to SPA; third tranche up to $5.56M principal, floor price $0.35","event_type":"debt","confidence":"high","bullets":["Third tranche: up to $5,555,556 principal for $5M purchase price; requires zero balance on prior tranches, Nasdaq listing, and stockholder approval.","Floor price raised to $0.35 per share (from $0.14) – conversion price cannot be less than $0.35.","Mandatory prepayment for equity line of credit: 33.3% (existing S-1) or 50% (future S-1) of net proceeds.","If Nasdaq deficiency notice exists, third tranche reduced to $3,333,333.60 principal for $3M purchase price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126711,"accession_number":"0001213900-25-124826","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa amends equity facility to lower floor price to $0.111/share, eliminates amortization on convertible note","event_type":"other_material","confidence":"high","bullets":["SPA Amendment lowers Floor Price to $0.111/share for up to 13.65M shares during Modification Period ending upon reverse stock split (expected Jan 2026).","After modification period, Floor Price reverts to $0.14/share, the original 20% of July 25, 2025 closing price.","Amendment No. 2 to convertible note eliminates monthly amortization payments, reducing near-term cash obligations.","Mandatory prepayment for any future Equity Line of Credit increased from 17.5% to 33.3% of net proceeds.","Both amendments effective Dec 22, 2025; company plans reverse stock split vote in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126710,"accession_number":"0001213900-25-112761","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profusa cuts net debt to $14M, gives 2026-2030 revenue targets","event_type":"other_material","confidence":"medium","bullets":["Net debt reduced from $48M to $16M in Q3 2025 and to $14M as of Oct 31, 2025.","Raised $12M from convertible PIPE note ($10M available) and $7M from ELOC ($93M remaining).","Completed reverse recapitalization with NorthView; Profusa equity value $155M.","Manufacturing build-out complete; product shipments and revenue expected in early 2026.","Seeks $200-250M revenue by 2030; near-term: 2026 potential $0.5-2M, 2027 potential $9-13M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126709,"accession_number":"0001213900-25-104814","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Profusa receives Nasdaq deficiency notice for MVPHS below $15M; 180-day cure period until April 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Profusa on Oct 27, 2025 that MVPHS was below $15M for 30 consecutive business days from Sep 12 to Oct 24, 2025.","Company has 180 calendar days, until April 27, 2026, to regain compliance with the MVPHS requirement.","Compliance can be regained if MVPHS closes at or above $15M for at least 10 consecutive business days.","If not compliant by April 27, 2026, Nasdaq may delist the common stock; company can appeal or apply to transfer to Nasdaq Capital Market.","Profusa intends to actively evaluate options to regain compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126708,"accession_number":"0001213900-25-103772","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026","event_type":"other_material","confidence":"high","bullets":["EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.","2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.","US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.","Estimates 35% European population coverage through intended distribution channels.","Targets $10.5B tissue oxygen market and >500M glucose monitoring population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126707,"accession_number":"0001213900-25-100494","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Profusa shareholders approve doubling authorized shares to 600M and conversion issuance","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 300M to 600M via amendment filed with Delaware Secretary of State on Oct 20, 2025.","Stockholders approved potential issuance of >19.99% of outstanding upon conversion of senior secured convertible notes under Nasdaq Rule 5635(d).","Votes: conversion issuance – 18,296,205 for, 858,635 against, 4,573 abstain; share increase – 17,968,659 for, 1,140,322 against, 20,432 abstain.","Special Meeting reconvened virtually on Oct 20, 2025; quorum of 19,159,413 shares out of 40,859,307 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126706,"accession_number":"0001213900-25-100443","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profusa publishes updated investor presentation; no material specifics in filing excerpt","event_type":"other","confidence":"low","bullets":["Updated investor presentation posted on company website on October 20, 2025.","Presentation includes forward-looking statements and risk factors.","No financial results, guidance, or material business updates disclosed in available excerpt.","Company tagline: 'Pioneering real time biochemistry that drives AI-led, personalized healthcare technologies.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126705,"accession_number":"0001213900-25-097141","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Profusa invests another $1M in Bitcoin; reduces stockholder quorum to 33%","event_type":"other_material","confidence":"high","bullets":["Second $1M investment in digital treasury assets (Bitcoin); total $2M to date.","Second Tranche ($2M purchase price, $2,222,222 principal) closed Sept 30; Control Agreement with Ascent and BitGo.","Bylaws amended to reduce quorum from majority to 33 1/3% of voting power for stockholder meetings.","Special Meeting adjourned Oct 7 due to lack of quorum; reconvened Oct 20 with same record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143503,"accession_number":"0001213900-25-088253","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Profusa receives Nasdaq MVLS and bid price deficiency notices; 180-day cure period","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Profusa on Sep 11, 2025, that MVLS was below $50M threshold from Jul 29 to Sep 10.","Separate bid price notice for failing to maintain $1.00 minimum closing bid over same period.","Company has until March 10, 2026 to regain compliance; stock continues trading under symbol PFSA.","Compliance requires MVLS >= $50M and bid price >= $1.00 for at least 10 consecutive business days.","If not cured, Profusa may face delisting or could apply to transfer to Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143502,"accession_number":"0001213900-25-084618","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Profusa stockholders approve $100M ELOC with Ascent Partners Fund","event_type":"other_material","confidence":"high","bullets":["Special meeting held August 29, 2025; 17.3M shares voted, quorum achieved.","Proposal to issue up to $100M common stock to Ascent Partners Fund under ELOC approved.","Votes: 17,206,846 FOR, 120,164 AGAINST, 7,139 ABSTAIN.","Approval satisfies Nasdaq Listing Rule 5635(d) for the previously disclosed ELOC transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143501,"accession_number":"0001213900-25-080457","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa amends convertible note deal: four tranches totaling $22.2M; conversion price reset with floor","event_type":"debt","confidence":"high","bullets":["Restructured SPA into four tranches: $10M (closed July 11), $2.22M, $5.56M, $4.44M; aggregate $22.2M principal.","Conversion price now lower of original or 95% of lowest 10-day VWAP; floor set at 20% of Aug 22 closing price.","Additional closings contingent on S-1 effectiveness, no Nasdaq deficiency, stockholder approval (proxy due Sept 5, 2025).","Notes priced at 90% of face value ($20M total purchase price for $22.22M principal); company released claims.","SPA amendment includes stockholder approval requirement; company must file definitive proxy by September 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143500,"accession_number":"0001213900-25-078539","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profusa appoints Peter O'Rourke as lead independent director, Fred Knechtel as CFO","event_type":"leadership","confidence":"high","bullets":["Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, joins board as lead independent director.","Fred Knechtel named CFO; previously led finance at Northrop Grumman, Stanley Black & Decker, DuPont.","Appointments effective upon close of business combination with NorthView Acquisition Corp (NVAC).","O'Rourke oversaw 1,300 VA facilities serving 9 million+ veterans; brings large-scale healthcare experience.","Knechtel has guided life-sciences and industrial companies through IPOs, M&A, and capital restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143496,"accession_number":"0001213900-25-076867","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K/A","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Profusa posts H1 net loss $5.1M; cash at $44K; going concern doubt persists","event_type":"other_material","confidence":"high","bullets":["Net loss $2.3M for Q2 2025, $5.1M for H1 2025; no revenue; R&D $0.8M, G&A $1.6M.","Working capital deficit $63.2M; cash $44K; management expresses substantial doubt about going concern.","Post-merger cash inflows include $1.3M from trust and $9M net PIPE note, offset by $3.4M payables.","Sponsor and stockholder shares locked up 6 months, subject to early release if stock >= $5 for 20/30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143499,"accession_number":"0001213900-25-073072","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026","event_type":"other_material","confidence":"medium","bullets":["Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.","First distributor partner in Spain for Lumee tissue oxygen platform; EU commercial launch targeted Q1 2026.","U.S. FDA submission planned mid-2026 with U.S. commercialization anticipated mid-2027 for oxygen monitoring.","Continuous glucose monitoring: human validation data expected in peer-reviewed journal; pivotal studies later 2026.","Secured $100M ELOC facility and implementing digital investment treasury plan to support growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143498,"accession_number":"0001213900-25-067855","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Profusa secures up to $100M equity line from Ascent Partners; proceeds to buy Bitcoin","event_type":"other_material","confidence":"high","bullets":["Securities Purchase Agreement with Ascent Partners Fund LLC for up to $100M in common stock purchases.","Share price set at 97% of lowest VWAP during 10-day valuation period; floor price is 20% of July 25 closing.","Proceeds must be used to purchase Bitcoin, except if cash balance falls below $5M; prohibited for exec comp or dividends.","Ascent receives warrant to buy 900k shares at $0.01; reduced to 450k if no purchases within 100 days.","Officers and directors executed lock-up agreements; registration rights filed within 10 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143497,"accession_number":"0001213900-25-065686","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","9.01","3.03","5.01","5.02","5.06","8.01"],"status":"ready","headline":"NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.","event_type":"m_and_a","confidence":"high","bullets":["Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.","Issued $10M principal PIPE convertible note to Ascent Partners at 10% OID, 18-month maturity.","Founder shares locked up for 8 months; other lock-up periods from 6 to 12 months.","Profusa is a clinical-stage digital health company with CE-marked Lumee Oxygen and Lumee Glucose in trials.","PIPE Investors subject to lock-up and registration rights; security interest granted on assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143495,"accession_number":"0001213900-25-061232","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"NorthView extends business combination deadline to August 22, 2025","event_type":"other_material","confidence":"high","bullets":["Stockholders approved extension of deadline for initial business combination from June 22, 2025 to August 22, 2025.","Amendment filed on July 1, 2025; prior filing mistakenly referenced July 22, 2025 and was corrected.","Approval by supermajority of 65% stockholder vote via written consent on June 27, 2025.","If no combination by new deadline, company will redeem 100% of offering shares and dissolve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161686,"accession_number":"0001213900-25-054360","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"NorthView stockholders approve merger with Profusa; all proposals pass","event_type":"m_and_a","confidence":"high","bullets":["All eight proposals approved unanimously; 4,979,599 shares voted (93.1% quorum).","Merger Agreement and charter amendments adopted; 52,784 shares redeemed, 5,295,527 outstanding.","Five directors elected: Lauren Chung (Class I), Jack Stover & Peter O'Rourke (II), Ben Hwang & Rajesh Asarporta (III).","Equity Incentive Plan and Employee Stock Purchase Plan also approved.","Proposals include non-binding advisory approval of New Profusa governance changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161685,"accession_number":"0001213900-25-052486","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NorthView buys 100K NVAC shares at $12.51 to cut redemptions; meeting adjourned to 4:30pm","event_type":"other_material","confidence":"high","bullets":["Investors purchased 100,000 shares at $12.51 under non-redemption agreement to boost trust cash for Profusa merger.","Stockholders redeemed 52,784 shares in connection with the special meeting to approve the business combination.","Special meeting originally 10am ET on June 9, 2025 adjourned to 4:30pm ET same day via teleconference.","Non-redemption agreement may increase likelihood of Nasdaq approval at closing of the business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161684,"accession_number":"0001213900-25-043468","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"NorthView enters non-redemption agreement to backstop trust account for Profusa merger","event_type":"other_material","confidence":"high","bullets":["I-Bankers and Dawson James agree not to redeem shares, ensuring trust balance stays above $1.25M threshold.","Agreement grants SPAC power of attorney to revoke any contrary redemption elections by the shareholders.","Shareholders collectively own at least $1,250,000 in shares (60% I-Bankers, 40% Dawson James).","Agreement effective until closing of merger with Profusa, Inc. or termination of Merger Agreement.","Redemption date may be extended to allow shareholders to accumulate additional shares before closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161683,"accession_number":"0001213900-25-039157","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"NorthView Acquisition Corp. names CBIZ CPAs as new auditor after Marcum resigns","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 30, 2025; CBIZ CPAs P.C. engaged same day.","Prior reports for FY 2023 and FY 2024 were unqualified except for a going concern emphasis paragraph.","No disagreements with Marcum on accounting principles or audit scope during the past two fiscal years.","CBIZ acquired Marcum's attestation business on Nov 1, 2024, prompting the switch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179786,"accession_number":"0001013762-25-002356","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"NorthView Acquisition Corp. extends business combination deadline to June 22, 2025 after stockholder vote","event_type":"other_material","confidence":"high","bullets":["Stockholders approved four proposals, including extending the deadline to June 22, 2025, and removing net tangible asset limitation.","532,958 shares were redeemed due to stockholder redemptions; 5,348,311 shares remain outstanding.","Company deposited $30,000 into trust account to support extension period.","If no business combination by June 22, 2025, the company will liquidate and redeem public shares.","Extension approved at special meeting March 21, 2025; all proposals passed with over 99% of votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179785,"accession_number":"0001213900-25-024796","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NorthView adjourns special meeting to March 21; sponsor commits $30K trust contribution for extension to June 22","event_type":"other_material","confidence":"high","bullets":["Special meeting adjourned to 11:00 a.m. ET on March 21, 2025, to allow holders who redeemed shares to reverse redemptions.","Sponsor revised contribution to $30,000 lump sum for the entire extension period (March 22 to June 22, 2025) instead of monthly payments.","Company waives right to withdraw up to $100,000 of trust interest for dissolution expenses and future tax expenses.","Estimated per-share redemption price from trust account is $12.20, after withdrawing ~$23,400 for taxes.","Proposed charter amendment extends deadline for business combination from March 22 to June 22, 2025, subject to shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179784,"accession_number":"0001213900-25-014987","cik":1859807,"company_name":"Profusa, Inc.","ticker":"PFSA","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"NorthView amends Profusa merger terms and secures up to $20M convertible note financing","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 4 lowers earnout revenue target for Milestone IV from $99.7M in FY2025 to $11.864M in FY2026.","Milestone III (Tasly JV) deadline extended to December 31, 2025; merger termination date pushed to March 22, 2025.","Securities Purchase Agreement for $22.22M principal convertible notes ($20M net after 10% OID); first tranche of $10M at closing.","Convertible notes mature in 18 months, 10% interest (24% default), conversion at lower of $10 or 95% of 10-day VWAP with MFN/down-round protections.","Lock-up agreements for NorthView officers/directors on shares post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}